News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Johnson & Johnson Must Pay Louisiana $257.7 Million Over Risperdal Marketing Practices
October 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Johnson & Johnson lost a $257.7 million jury verdict in Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
China
FDA raises bar for foreign site inspections as China trials surge
September 2, 2026
·
4 min read
·
Heather McKenzie
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac
Drug pricing
9 midsize drugmakers climb aboard Trump’s MFN train
September 1, 2026
·
2 min read
·
Tristan Manalac
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
August 31, 2026
·
2 min read
·
Annalee Armstrong
